Yes again great research and story telling here that aligns with our aspirations for investing in PAR.
It wouldn't be a waste of time I believe if we start discussing the "blind spots" that are present with our thesis given this is PR and the PAR teams first live run together at achieving certification. Moreover, how relevant DMOAD is to our near ten future success is still a big question mark as PAR have yet to articulate how it will be influenced by the various P3 streams.
If we get some consensus of what shareholders collectively have assessed as possible "blind spots" (unknown risks) it could then be feedback to PR to focus his future presentations.
- Forums
- ASX - By Stock
- Bond plus 1
PAR
paradigm biopharmaceuticals limited..
Add to My Watchlist
3.23%
!
45.0¢

Yes again great research and story telling here that aligns with...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
45.0¢ |
Change
-0.015(3.23%) |
Mkt cap ! $184.8M |
Open | High | Low | Value | Volume |
47.0¢ | 47.5¢ | 43.0¢ | $162.8K | 357.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 68560 | 45.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
46.0¢ | 5665 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 30560 | 0.450 |
1 | 8166 | 0.440 |
2 | 15000 | 0.435 |
3 | 102031 | 0.430 |
4 | 161397 | 0.425 |
Price($) | Vol. | No. |
---|---|---|
0.470 | 37781 | 3 |
0.475 | 40515 | 5 |
0.480 | 205598 | 5 |
0.485 | 23239 | 2 |
0.490 | 18000 | 2 |
Last trade - 10.19am 07/07/2025 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online